Virax Biolabs Group Limited (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, have signed a lease agreement with BioCity Glasgow, establishing a research laboratory in Glasgow, United Kingdom.
The state-of-the-art facility is within proximity to top-ranked institutions including the Universities of Glasgow and Edinburgh, and major hospitals and clinics in Scotland. This convenient location facilitates close cooperation with the National Health Service, access to fresh blood samples and blood banks for ongoing and future assessments, and collaborations with local research groups specialized in immunology. As part of BioCity, we have access to cost-effective community facilities, and more broadly, access to a number of additional communities of experts based in incubators across the UK Science Parks Association and the United Kingdom.
“Establishment of a facility in Glasgow extends our research capacity, enabling us to simultaneously and independently develop multiple new products within our ViraxImmune™ platform from early to late stage, including verification and validation,” said Cameron Shaw, Virax’s chief operating officer. “The lab is designed to meet current good manufacturing practices, giving us better supply chain control for manufacturing components of our ViraxImmune™ kits.”
“We are delighted to welcome Virax Biolabs to our growing life science innovation ecosystem at BioCity Glasgow and our Pioneer community of UK Science Parks Campuses,” said John Mackenzie, Director (Scotland), The Pioneer Group. “Pioneer is dedicated to helping young companies succeed in delivering life-changing health solutions that will shape our future. We believe in the mission driving Virax’s business and have no doubt that Virax’s technology will strengthen our global approach to immune health.”
About Pioneer Group
Pioneer Group’s mission is to help life sciences and high-tech businesses to thrive in tackling challenges in both human and planetary health. Across the UK and Ireland, Pioneer leads the way in integrating the provision of mission critical real estate, venture building and venture investment. Since 2003 its connected cluster model has provided powerful sector-specific, business-focused ecosystems in which businesses are more likely to succeed.
Real Estate
As a leading developer and operator of life science and high-tech campuses, Pioneer Group manages over £1 billion of real estate (over 4 million square feet) in 12 leading innovation locations across the UK and Ireland. Pioneer’s campuses offer a range of flexible, specialist laboratory, industrial and office space to support scientists, technologists, engineers and entrepreneurs on every step of the innovation journey from R&D to manufacturing. Pioneer’s campuses are home to organisations ranging from start-up to multi-national.
About BioCity Glasgow
BioCity Glasgow has an outstanding reputation in pharmaceutical and biotherapeutics research. A former MSD research facility with pharma grade site security, this 20-acre biotech incubator has an assortment of fully accessible, contemporary offices and lab space to rent.
Located between Glasgow and Edinburgh on the M8, BioCity Glasgow delivers more than simple office space. With access to on-site to MHRA licensed controlled conditions, cryostorage, a compound management library and a nurturing business community designed to help you flourish, this Scottish life sciences cluster provides the perfect setting for businesses of all sizes to lay down roots.
Nestled in amongst landscaped gardens, and mature trees. Companies based here enjoy a break from work in ‘Nowhere’, a stylish coffeehouse co-working space with air hockey, a pool table, a gym, cosy lounge spaces and patio garden.
Life science start-ups based here make use of the ample car parking, easy access to the M8, two airports and two local train stations only a short distance away.
Lab Space to Rent Glasgow | BioCity Glasgow | Pioneer Group (thepioneergroup.com)
About Virax Biolabs Group Limited.
Founded in 2013, Virax Biolabs Group Limited is an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases. In addition to distributing an array of in-vitro diagnostic test kits, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing can be particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Company Contact:
Virax Biolabs Group Limited
Phone: +44 020 7788 7414
Email: info@viraxbiolabs.com
Media and Investor Contact:
Nic Johnson and Adanna Alexander
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
